Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$118.68
pos +0.00
+0.00%
Today's Range: 118.02 - 120.00 | CELG Avg Daily Volume: 5,390,500
Last Update: 03/27/15 - 4:00 PM EDT
Volume: 0
YTD Performance: 6.10%
Open: $0.00
Previous Close: $117.66
52 Week Range: $66.85 - $129.06
Oustanding Shares: 800,590,656
Market Cap: 94,197,496,585
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 14 15 14 16
Moderate Buy 1 1 1 1
Hold 4 4 4 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.47 1.45 1.47 1.26
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 49.23
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
49.23 49.20 27.26
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.70% 66.90% 204.15%
GROWTH 12 Mo 3 Yr CAGR
Revenue 18.10 0.58 0.16
Net Income 37.90 0.52 0.15
EPS 42.00 0.72 0.20
Earnings for CELG:
EBITDA 2.94B
Revenue 7.67B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.90 $1.03 $4.32 $6.09
Number of Analysts 3 3 3 3
High Estimate $0.93 $1.12 $4.47 $7.21
Low Estimate $0.87 $0.98 $4.23 $5.45
Prior Year $0.73 $0.80 $3.36 $4.32
Growth Rate (Year over Year) 23.29% 29.17% 28.57% 40.97%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Mar 27, 2015 | 5:21 AM EDT

If there is no catalyst, I'd join those who sell on a bounce.

By

Jim Cramer

 | Mar 26, 2015 | 5:47 PM EDT

It takes a village of positive reports to sustain market.

By

Robert Lang

 | Mar 23, 2015 | 9:31 AM EDT

Where are Celgene, Isis and CVS heading?

By

Jim Cramer

 | Mar 23, 2015 | 6:00 AM EDT

Here are healthcare stocks of all shares and sizes with strong charts.

By

Jim Cramer

 | Mar 21, 2015 | 2:30 PM EDT

Own them, or take something off the table?

By

Jim Cramer

 | Mar 20, 2015 | 10:53 AM EDT

I really like the stocks. But I also like making money on stocks.

By

Jim Cramer

 | Mar 19, 2015 | 6:52 PM EDT

Market backtracks on skepticism over biotechs.

By

Jim Cramer

 | Mar 4, 2015 | 12:31 PM EST

Sector could regain its leadership role.

updateRBC Healthcare Conf.

Feb 24, 2015 | 6:51 AM EST

RBC Healthcare Conference

By

Robert Moreno

 | Feb 19, 2015 | 2:10 PM EST

Chart setups in Celgene, Medivation and AMAG Pharmaceuticals.

Cover story in Barrons: "JPMorgan Rising" - JPM was added to my Best Ideas List and "Trade...
Darden Restaurants' (DRI) CFO sold 66,863 shares on March 24, 2015 for an average price of...
We did not end up holding the pullback to the last time/price low in NFLX. I have run som...
The Biotech iShares (IBB) fund closed up nearly 2% on the day, but was down over 5% on th...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.